Tarsus Pharmaceuticals, Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Tarsus Pharmaceuticals (NASDAQ, ~$1.7B market cap) agreed to acquire Alkeus Pharmaceuticals via merger. Base consideration: $270M cash upfront plus $180M in Tarsus stock (~$61.38/share) for a total upfront value of ~$450M. Additional contingent payments: up to $350M in milestone payments ($250M on FDA approval of ALK-001 in US; $100M on first commercial sale in US) plus royalties on net sales (tiered 5%-15% depending on sales level and patent/exclusivity status, capped at 10-year term or patent/exclusivity expiration). Transaction includes $5M adjustment escrow, earnout structure with post-closing true-up procedures, and key employee retention arrangements. Merger closing anticipated Q3 2026.
Why this rating
Acquisition price (~$450M upfront cash+stock) represents ~26% of Tarsus's $1.7B market cap—material but not transformational. Contingent payments add risk/opportunity but are performance-based. Net neutral on near-term stock absent deal certainty issues.
Price action (we called it neutral)
before filing · preread $81.12 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.